Original Agenda
We are actively working with our speakers to confirm their availability for the virtual event. Initial response from our speakers has been very positive, and we are optimistic we will have the new programs ready to share here soon.

Display of Biologics track banner

The Seventh Annual Display of Biologics program at PEGS Europe has become the cornerstone of the PEGS Europe Summit and will feature visionaries and novel technologies to generate new classes of therapy in the field of biologics. Display technologies, including phage, yeast, bacterial, mammalian, etc., have resulted in a staggering array of bispecific antibodies, antibody-drug conjugates, and immunotherapies. Genome editing, deep sequencing, single-cell analysis, machine learning, and computational tools are improving library design, selection, and screening of drug candidates. Join the stellar faculty at this year’s meeting to discuss the promising future of display of biologics.

Monday, 9 November

08:00 Short Course Registration
09:00 Recommended Short Course*
SC1: Advanced Course on Making Antibody Libraries in Phage and Yeast

*Separate registration required. See short course page for details.

12:00 Conference Registration

CUTTING-EDGE DRUG DEVELOPMENT FOR INFLAMMATORY AND AUTOIMMUNE DISEASE

13:30 Welcome by Conference Organizer

Christina Lingham, Executive Director, Conferences and Fellow, Cambridge Healthtech Institute

13:35

Chairperson's Opening Remarks

Ahuva Nissim, PhD, Professor, Antibody and Therapeutic Engineering, William Harvey Research Institute, Queen Mary University of London
13:45 KEYNOTE PRESENTATION:

Why We Develop Autoimmune Diseases: Hyperstimulation of the Immune System

Yehuda Shoenfeld, MD, FRCP, MaACR, Past Incumbent of the Laura Schwarz-Kipp Chair, Research of Autoimmune Diseases, Tel-Aviv University

Autoimmune diseases are genetics, HLADRB1 haplotypes are notorious in their prevalence among subjects with diverse autoimmune diseases. Hyperstimulation of genetically prone subjects bearing HLABRB1 may lead to autoimmunity. Check points inhibitor (CPI) therapy unleashing the breaks on the immune system was found to cure several untreatable cancers. Yet the toll was realized to be emergence of panoply of autoimmune conditions. Mainly among HLA DRB1 bearers. Silicone breast implants (SBI) where found to induce different autoimmune conditions. Mainly due to the adjutancy characteristics of the silicone. It happened mainly among HLADRB1 bearers. Thus, CPI and SBI are 2 proofs-of-concept for the importance of genetics with an aggressive immune system and environmental factors that are association with hyper stimulated immune system.

14:15

Engineering the Next Generation of Therapeutics

John Delaney, PhD, Director, Research Technologies and Collaborations, Amgen
14:45

Targeting Subcellular Trafficking Behavior for the Design of Therapeutic Antibodies

E. Sally Ward, PhD, Director, Translational Immunology, and Professor, Molecular Immunology, Centre for Cancer Immunology, University of Southampton

The use of antibody engineering combined with subcellular trafficking analyses to design therapeutic antibodies in two areas will be discussed: First, the development of engineered antibodies that clear pathogenic antibodies. Second, the design of antibody-drug conjugates (ADCs) that deliver their cytotoxic payload more efficiently to lysosomes within cells, resulting in a strategy to generate ADCs that are effective at lower doses.

15:45 Networking Refreshment Break

PLENARY KEYNOTE SESSION

16:15 KEYNOTE PRESENTATION:

Keynote Chairperson's Remarks

Denise L. Faustman, MD, PhD, Associate Professor & Director, Immunobiology Labs, Massachusetts General Hospital
16:20 KEYNOTE PRESENTATION: Learning from What Works: Dissection of Successful Cancer Clearance by the Immune System
Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Division of Infection and Immunity, Cardiff University School of Medicine

What is the key to success? How do some rare patients spontaneously clear extreme cancer? What is being recognised by T cells during successful tumour-infiltrating lymphocyte or T cell checkpoint therapy? We have developed two new methodologies that allow rapid determination of the ligand recognised by any ‘orphan’ T cell clone. These techniques have enabled us to address these questions and discover novel cancer-associated epitopes expressed by most cancers.

17:05 KEYNOTE PRESENTATION:

mAbs vs. Bugs: Antibody Therapies for Infectious Disease

Steve Martin, PhD, Vice President, Biopharm Discovery, GlaxoSmithKline

This year’s coronavirus pandemic has provided a stark reminder of the threat to global health posed by infectious disease and the need for new treatments. Renewed attention has been brought to the potential of antibodies as anti-infective therapeutics, which historically has been a challenging area for drug discovery. Synergies between modern vaccine development approaches and antibody discovery technologies offer new opportunities in the fight against our microbial foes.

17:50 Welcome Reception in the Exhibit Hall with Poster Viewing
19:00 End of Day

Tuesday, 10 November

07:45 Registration and Morning Coffee

CUTTING-EDGE DRUG DEVELOPMENT FOR INFLAMMATORY AND AUTOIMMUNE DISEASE (CONT.)

08:30

Chairperson's Remarks

Ahuva Nissim, PhD, Professor, Antibody and Therapeutic Engineering, William Harvey Research Institute, Queen Mary University of London
08:35 Post-Translational Modification and Disease-Potential Targets for Therapy
Ahuva Nissim, PhD, Professor, Antibody and Therapeutic Engineering, William Harvey Research Institute, Queen Mary University of London

We discovered and developed the concept that auto reactivity in arthritis is against neoepitopes that is formed as a result of oxidative post translational modification (oxPTM) collagen type II (oxPTM-CII) that are formed specifically in the arthritic joints. Hence, autoantibodies to oxPTM-CII are biomarkers that can be utilised for early diagnosis and for stratification of patients with RA. We showed that specific targeting of a payload drug by anti-oxPTM-CII antibody to inflamed arthritic joints (Etanercept or viral IL-10) and hence nanoparticles loaded with multiple drugs. This resulted in significantly enhanced therapeutic effecacy compared with non-targeted systemic treatments. We also showed that anti-oxPTM-CII antibodies can detect very early OA before evident cartilage erosion.

09:05

Early Detection of Osteoarthritis in the Rat with an Antibody Specific to Type II Collagen Modified by Reactive Oxygen Species

Anne Gigout, PhD, Group Leader in vivo Pharmacology, Galapagos, Romainville, France

We used an antibody specific to oxidative post translationally modified type II collagen (oxPTM-CII) to stain rat cartilage in two different chronic osteoarthritis models. Several time points were evaluated as early as one day post operation. We could observe that oxPTM-CII staining is mainly localized in the deep zone and is detectable before the appearance of cartilage lesions. It indicates that oxPTM-CII could serve to detect early osteoarthritis.

09:35 Problem Solving Breakout Discussions*

*Topics to be announced.

10:30 Coffee Break in the Exhibit Hall with Poster Viewing

IMMUNO-MODULATION FROM PHAGE AND YEAST DISPLAY LIBRARIES

11:10

Chairperson's Remarks

Gregory A. Weiss, PhD, Professor, Chemistry, Pharmaceutical Sciences, Molecular Biology & Biochemistry, University of California, Irvine
11:15

Allosteric Anti-Tryptase Antibodies for the Treatment of Mast-Cell Mediated Severe Asthma

Henry Maun, PhD, Associate Director, External Innovation, Roche
11:45 Modulating the Receptor Binding Site of Immunoligands for Enhanced Potency and Efficacy
Stefan Zielonka, PhD, Associate Director, Protein Engineering & Antibody Technologies, Merck KGaA

Immunoligands are bifunctional antibody-like molecules composed of a tumor targeting arm as well as of a natural ligand of an activating receptor on immune cells, thereby mediating immune cell redirection. We have generated affinity-optimized variants of a ligand for immune cell activating receptors. When reformatted into a bispecific immune cell engager context, those affinity-enhanced variants facilitated substantially increased killing of tumor cells compared to immune cell engagers harboring the wild-type ligand. Moreover, release of pro-inflammatory cytokines was substantially elevated. Taken together, affinity maturation of ligands for activating receptors on immune cells represents an alternative strategy for the generation of potent immune cell engagers.


Oleh Petriv, PhD, Vice President, New Technology Development, AbCheck

AbCheck discovers and optimizes monoclonal antibodies for therapeutic applications leveraging several proprietary platforms including in vivo and in vitro technologies. AbCheck developed a new approach to discover candidate leads based primarily on functional criteria which is assessed at single-cell level in cell-based assays. We will present data generated using high-throughput microfluidics to illustrate the potential of this new technology.

Joseph Rucker, PhD, Vice President, Research & Development, Integral Molecular

Oncology targets Claudin 6 (CLDN6) and 18.2 (CLDN18.2) are overexpressed in select cancers but are absent in most adult healthy tissues. Using our MPS Antibody Discovery platform, we discovered and humanized lead candidate antibodies that bind unique residues on CLDN6 but not closely related receptors CLDN9, CLDN3, and CLDN4, or members of the human proteome. We also present a panel of humanized CLDN18.2 MAbs with picomolar affinities that are superior to the clinical-stage benchmark.

Richard Buick, PhD, CTO, Fusion Antibodies
13:45 Dessert Break in the Exhibit Hall with Poster Viewing

NEXT-GENERATION PLATFORMS FOR TARGET DISCOVERY

14:15

Chairperson's Remarks

Ana Barbas, PhD, Coordinator, Bayer Satellite Laboratory, iBET, Bayer Portugal SA
14:20 KEYNOTE PRESENTATION:

Highly Targeted Anticalin® Therapies

Hitto Kaufmann, PhD, CSO & Senior Vice President, Pieris Pharmaceuticals GmbH

A number of Anticalin-based new therapeutic entities are currently in clinical and preclinical development. We are gaining an increasing understanding of these molecules as they are being developed either as inhalable proteins treating respiratory diseases or as multi-specific injectables in immune-oncology. This translates into an enhanced discovery and development platform for a broad pipeline of highly targeted biologics.

14:50 Rapid Identification of Highly Potent Fully Human Anti-CCR-1 Antagonist mAbs
Martin Scott, PhD, Scientific Leader & Associate Fellow, GlaxoSmithKline

Complex cellular targets such as GPCRs, ion channels, and other multi-transmembrane proteins represent a significant challenge for therapeutic antibody discovery, primarily because of poor stability of the target protein upon extraction from cell membranes.  Here we have used different membrane-bound antigen formats to identify and optimise anti CCR-1 functional antibodies using an in vitro yeast-based antibody discovery platform (AdimabTM). These data exemplify a methodology to generate potent fully-human mAbs for challenging targets rapidly using whole cells as antigen and also define a route to the identification of affinity-matured variants.

15:20 Phenotypic Discovery of Antibody-Target Combinations and Deep Mining of Complex Antibody Pools
Anne Ljungars, PhD, Senior Research Scientist, Preclinical Research, BioInvent International AB

The antibody drug development field suffers from a crowded target space and an approach for discovery of both novel antibodies and targets is phenotypic screening, using phage display and selection on whole cells, followed by functional testing and target deconvolution. In this strategy, the generated pool of antibodies will be very complex and by applying various mining technologies antibodies against a broad range of cell surface receptors are discovered.

Lauri Peil, PhD, Key Account and Technology Officer, Icosagen Cell Factory

Fast growth of therapeutics field over the last few years has created an urgent need for efficient and scalable methods suitable for the production of antibodies and other recombinant proteins for pre-clinical studies and also for diagnostics. Latest case studies of expressing SARS-CoV-2 proteins for diagnostic use and for antibody discovery using our QMCF protein expression technology platform are presented, together with preliminary data on SARS-CoV-2 specific antibodies discovered using our HybriFree platform.

16:20 Refreshment Break in the Exhibit Hall with Poster Viewing

MAKING ANTIBODIES RAPIDLY TO COMBAT PANDEMIC VIRUSES

16:55

Chairperson's Remarks

David Lowe, PhD, Senior Director, R&D, Antibody Discovery and Protein Engineering, AstraZeneca
17:00 Pushing the Limits of Antiviral Immunotherapy
Ron Diskin, PhD, Senior Scientist, Structural Biology, Weizmann Institute of Science

Immunotherapy holds a great promise for fighting emerging and reemerging viruses that may cause pandemics. Monoclonal antibodies make our primary tool for fighting such viruses, but isolating them takes time, and not always they have the required potency to be clinically relevant. I will discuss the characterization of monoclonal antibodies, structure-based approaches for augmenting antibodies as well as alternative immunotherapeutic approaches.

17:30 Human Neutralizing Antibodies against SARS, MERS and Emerging Coronaviruses: Implications for Future Immunotherapy
Wayne Marasco, MD, PhD, Professor of Medicine, Cancer Immunology & Virology, Dana-Farber Cancer Institute

Developing human neutralizing antibodies (nAbs) against emerging viral pathogens can be seriously delayed due to limited access of blood specimens from acute/convalescent infected individuals due to privacy, public safety, regulatory and national security concerns. However, seminal discoveries of nAbs for emerging coronaviruses have also been made the old-fashioned way through antibody phage display using non-immune libraries. I will discuss the lessons that we have learned for nAb discovery during these outbreaks.

18:00 Rapid Discovery of Anti-Viral Antibodies and Development as Gene Therapies for Pandemic Prevention
David Lowe, PhD, Senior Director, R&D, Antibody Discovery and Protein Engineering, AstraZeneca
18:30 Close of Display of Biologics